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LP9 and LP3 mesothelial cells were obtained from the Coriell Institute. LP9, LP3 and primary 
CAMs and HPMCs were cultured in media containing 40% Ham's F-12, 40% Medium M199 
(Thermo Fisher Scientific, Cat# 11150-067), 20% FBS. Primary HGSOC cell line OC8 was a 
generous gift from Dr. Weiping Zou (1), and was cultured in RPMI 1640 media supplemented 
with 10% FBS. Primary HPMCs and CAOV3 cell line was a generous gift from Dr. Katherine C. 
Fuh (2). Ovarian cancer cell lines OVCAR8, CAOV3 and SNU119 were cultured in DMEM 
supplemented with 10% FBS (2). In addition, cells were tested upon receipt for viability, cell 
morphology, and the presence of Mycoplasma and viruses. All cells were cultured at 37°C supplied 
with 5% CO2.  
Primary mesothelial cell isolation 
Ascites-derived primary CAM1 and CAM2 cells were isolated from the malignant ascites of 
ovarian cancer patients (Supplemental Table 1) at Stanford under a Stanford University 
institutional review board–approved protocol with informed consent. As previous described (20), 
after brief centrifugation at low speed, ascites cell pellets were seeded at high density and cultured 
on Poly-L-lysine (Sigma Aldrich) covered surface in culture medium until cell confluence was 
reached. Under this culture condition, mesothelial cells were enriched without contamination of 
other cell types (3). Primary HPMCs were derived from omentum of patients with benign disease 
as described previously (2). All primary mesothelial cells were used for studies within six passages. 
Primary mesothelial cell staining  
Primary mesothelial cells were seeded into 8-well chamber slides (Thermo Fisher Scientific), and 




(Dako) for 10 minutes at room temperature, and then stained in primary antibody solution at 4°C 
overnight. The primary antibodies included antibodies against Calretinin (Invitrogen, 1:50), 
Vimentin (Thermo Fisher Scientific, 1:50), Cytokeratin 8 (Abcam, 1:100), FSP1 (Novus 
Biologicals, 1:100), CD31 (Abcam, 1:20), FITC-CD45 (Thermo Fisher Scientific, 1:20) and 
EpCAM (Abcam, 1:50).  The following day, secondary antibodies conjugated with Alexa Fluor 
Dyes (Thermo Fisher Scientific, 1:500) were incubated for 1 hour at room temperature, except for 
FITC-CD45 stained samples. DAPI (Sigma Aldrich) was used for nuclear counterstaining at 0.1 
µg/ml, and representative images were taken under the Leica SPE microscope to confirm 
mesothelial cell purity.  
In vivo cisplatin response study 
To establish co-injected xenograft models, 1 × 106 cancer cells were mixed with or without 1 × 
106 mesothelial cells immediately before injection in 50% Matrigel solution (Corning) in PBS. 
Cell suspensions were injected subcutaneously into the left flank of 8-12 week-old female Rag2-/-
IL2rg-/- mice. To examine the influence of LP9 co-culture on cancer cell chemoresistance, cancer 
cells were monocultured or co-cultured with LP9 in vitro as described for 2 weeks and then cancer 
cells were injected subcutaneously into the left flank of 8-12 week-old female Rag2-/-IL2rg-/- mice 
at 1 × 106 cell number in the 50% Matrigel solution. Tumor incidence varied among injection 
groups, and the percentage of mice with palpable tumors within each group is as shown in Figure 
3. For LP9 CM preincubation of tumor cells, cancer cells were preincubated in control medium or 
LP9 CM with control antibody or an anti-OPN antibody at 20 µg/ml for 10 days, and then injected 
subcutaneously into the left flank of 8-12 week-old female Rag2-/-IL2rg-/- mice at 0.5 × 106 cell 
number in the 50% Matrigel solution. When the tumors reached an average volume of 100-160 




administered intraperitoneally at 5 mg/kg every three days for a total of three treatments as 
indicated. Tumor size was measured every 2 or 3 days using calipers and tumor volumes were 
calculated using the formula: tumor volume (mm3) = (length x width2)/2. Mice with morbidities 
as determined by the Stanford veterinary staff (example skin lesions) were excluded from tumor 
growth and weight analysis. 
 
OPN aptamer treatment in the ID8 tumor model 
OPN apatamer and mutant aptamer were synthesized as previously reported (4). To test the in vivo 
therapeutic potential of OPN aptamer, 2 x 106 ID8 cells were injected to 8-12 week-old female 
C57BL/6J mice intraperitoneally. Ten days after cancer cell injection, mice were treated with 
either cisplatin with mutant aptamer, or OPN aptamer, or the combination of cisplatin with OPN 
aptamer. Cisplatin was administrated intraperitoneally at 3 mg/kg every three days for a total of 
three consecutive injections. OPN aptamer or mutant aptamer was administrated intraperitoneally 
at 100nmol/kg every day until the end of experiment. Tumor number and weight, ascites volume 
and omentum weight was measured at the end of experiment. 
For ID8 ascites cells, total cell suspension was deposited by cytospin onto glass slides. 
Cells were then fixed in 10% formalin for 20 mins, and blocked. Cells were permeabilized with 
0.2% Tween-20 in PBS, blocked in serum-free protein block (Dako) for 10 minutes at room 
temperature, and then stained in primary antibody (Goat Anti-osteopontin Antibody, Novus 
Biologicals, 1:100; Rabbit Anti-calretinin Antibody, Invitrogen, 1:50) solution at room 
temperature for 1 hour. After washing, anti-rabbit or anti-goat secondary antibodies conjugated 
with Alexa Fluor Dyes were added for 30 minutes at room temperature. DAPI (Sigma Aldrich) 





In vivo limiting dilution assay 
For the LP9 co-injected model, cancer cells (cell number 100, 1000, or 10000) were mixed with 
or without LP9 cells at 1:1 ratio right before injection, and cell suspensions were injected 
subcutaneously into the left flank of 8-12 week-old female Rag2-/-IL2rg-/- mice in 50% Matrigel 
solution (Corning) in PBS. For the LP9 co-culture model, cancer cells were monocultured or co-
cultured with LP9 in vitro as described for 2 weeks and cancer cells (cell number 100, 1000 or 
10000) were injected subcutaneously into the left flank of 8-12 week-old female Rag2-/-IL2rg-/-
mice in the 50% Matrigel solution. Tumor appearance were closely monitored, and around 1 month 
after inoculation, mice were sacrificed to check tumor formation on the injected site. 
Indirect co-culture of cancer cells with mesothelial cells 
Ovarian cancer cells were seeded into the bottom chamber of 75 mm co-culture dishes (Corning, 
Cat# 3419) at 4-6 × 104 cells. After 8 hours, 12 × 104 LP9, LP3 or primary CAMs were seeded 
onto the upper insert of 0.4 µm pore size. The inserts allowed for interaction between the two cell 
types without physical contact. The co-culture system was incubated at 37°C for a total of 7 days 
and then cancer cells were passaged and/or checked for phenotypic changes. For examination of 
HPMCs after co-culture with ovarian cancer cells, HPMCs were grown on the bottom, while 
cancer cells were grown on the upper insert of 0.4 µm pore size for a total of 7 days.  
Generation of conditioned medium and cell treatments 
Cells were cultured at 80-90% confluence in 1% FBS culture medium. After 72 hours, the 
conditioned media from cultures were transferred to Amicon Ultra-15 Centrifugal Filter units 
(Millipore) with 10 KDa molecular weight cut-off through a 0.45-mm syringe filter and 




concentrated medium by adding fresh medium. The concentrated medium was then mixed at 1:1 
ratio with basal medium for utilization in further studies. For some experiments, Proteinase K was 
added to CM as previously reported (1). For OPN inhibition experiments, the anti-OPN 
neutralizing antibody (R&D) was added at the concentration of 20 µg/ml to the cell media. For 
CD44 and integrin receptors blocking experiments, the anti-CD44 blocking antibody (Bioxcell) 
and RGD (Abcam) was added at the concentration of 10 µg/ml. For TGFβ1 related experiments, 
human recombinant TGFβ1 (Peprotech) dissolved in 4 mM HCL was applied at the concentration 
of 10 ng/ml for 3 days. SB431542 (Millipore) was added at the concentration of 10 µM in cell 
media as previously reported (5). 
Cell viability assay 
Ovarian cancer cell lines were seeded in 96-well plates after treatment. Cells were then treated 
with cisplatin, carboplatin or paclitaxel at two drug concentrations that span IC50. After 2-3 days, 
cell viability assays were performed using CellTiter-Glo Viability Assay (Promega) or CellTiter-
Blue Viability Assay (Promega) and a microplate reader. The percentage of cell viability was 
expressed relative to that of untreated control in each group. 
Annexin V assay 
APC Annexin V kit (Biolegend, Cat# 640920) was used following the manufacturer’s instructions. 
In general, cells were dissociated with 0.02% EDTA solution, washed with 1% BSA in PBS. Cells 
were then stained with 5 µL APC-Annexin V in 100 µL Annexin V binding buffer and Sytox Blue 
(Biolegend, 50 nM) on ice and then samples were run on an LSR Fortessa X-20 (BD) and analyzed 
using FlowJo software (TreeStar). 
Sphere formation assay 




attachment plates (Sigma Aldrich). The sphere formation medium was serum-free DMEM or 
RPMI 1640 supplemented with 5 µg/ml insulin (Sigma Aldrich), and 20 ng/ml human recombinant 
EGF (Thermo Fisher Scientific), 10 ng/ml FGF-basic (Sigma Aldrich), and 2% B27 (Invitrogen). 
At the end point, the spheres were photographed and the number of spheres (>50 µm) was counted 
under microscope. 
Real time PCR 
The RNA was reverse transcribed into cDNA using High-Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher Scientific). Real-time PCR was performed using iTaq™ Universal 
SYBR® Green Supermix (Bio-Rad). Relative mRNA expression of target genes was determined 
using the standard curve method, and then normalized to GAPDH mRNA as internal control. The 
primers of target genes for the real-time PCR are listed in Supplemental Table 5.  
Cytokine array 
A cytokine array (Raybiotech, Cat# AAH-CYT-5-4) was utilized according to the manufacturer’s 
instructions. Integrated dot intensity was examined using Image J.  
ELISA  
Cells were seeded at 2 × 105 cells in duplicates or triplicates in 6-well tissue culture plates and 
allowed to adhere overnight. Cells were then grown in serum-free medium for 24 hours. The cell 
supernatants were collected by medium centrifugation and filtration through 0.45 µm filter. OPN 
ELISAs were processed in accordance with the manufacturer’s instructions (R&D, Cat# DOST00). 
CAM1 and CAM2 have two biological replicates, while all other samples have 3 biological 
replicates. TGFβ1 ELISA was processed in accordance with the manufacturer’s instructions of 
TGFβ1 ELISA kit (R&D, Cat# DB100B) and sample activation kit (R&D, Cat# DY010).  




Two shRNAs against OPN (SPP1) were purchased from Sigma Aldrich (TRCN0000004875 and 
TRCN0000342616). For the generation of lentiviral particles, 293T cells were transfected by a 
cocktail of 1.5 µg shOPN or non-targeting control constructs, packaging vectors (0.5 µg of VSVG 
and 2 µg of Δ8.2) and Lipofectamine 2000 (Thermo Fisher Scientific). The lentiviral supernatants 
were harvested at 48 and 72 hours post-transfection using 0.45 µm filter, and added to LP9 cells 
with 5 µg/ml Polybrene. The lentivirus infected LP9 cells were then selected with puromycin (1 
mg/ml) for 5 days until control cells without infection were all dead. 
Western blotting 
Cells were lysed in RIPA buffer with the addition of protease or phosphatase inhibitors and cleared 
by centrifugation (12,000 rcf for 15 minutes at 4°C). Proteins were separated by gel electrophoresis 
and 20–50 µg of protein was subjected to reducing SDS/PAGE using standard methods (6). Blots 
were probed with the primary antibodies (1:1000) overnight at 4°C; or anti-GAPDH antibody 
(1:2000) as loading control. After washing, blots were incubated with anti-rabbit or anti-mouse 
IgG HRP-linked secondary antibodies (Cell Signaling Technologies, 1:5000) at room temperature 
for 1 hour. Immunoblots were developed with SuperSignal West Dura Extended Duration 
Substrate or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) 
and visualized with ChemiDoc XRS. Imaging system equipped with Image Lab Software (Bio-
Rad). 
Aldefluor assay 
For the detection of ALDH1 activity, Aldefluor assay kit (STEMCELL Technologies, Cat# 01700) 
was used according to the manufacturer’s instructions. Briefly, dissociated cancer cells from co-
culture or xenografts were resuspended in Aldefluor assay buffer containing ALDH1 substrate at 




with 50 mM diethylaminobenzaldehyde (DEAB) to define negative gates, the other half was used 
as test tube in the absence of DEAB.  
          For analysis on in vivo xenografts, subcutaneous tumors were carefully dissected. Tumors 
were digested in 20 µg/ml Liberase and 400 µg/ml DNase I in RPMI 1640 for 30 minutes at 37°C 
with rotation. After tissue digestion, loosely attached tissues were minced into 2-5 mm pieces using 
scissors, mashed with the plunger of 5 ml syringe and filtered through a cell strainer to get rid of 
tissue clumps. The filtered mixture was then added with 30% Percoll gradient in RPMI 1640 and 
centrifuged with no brakes for 20 minutes. The cell pellets were then resuspended in full RPMI 
1640 medium to generate single cell suspensions. After processed with Aldefluor assay procedures 
as mentioned above, cell samples were stained with fluorescent labeled antibodies in Aldefluor 
assay buffer for 20 minutes at 4°C. After antibody labeling, cells were added with Sytox Blue and 
analyzed for ALDH1 percentage on an LSR Fortessa X-20 (BD) and analyzed using FlowJo 
software (TreeStar). The staining antibodies included Mouse Anti-EpCAM Antibody eFluor 660 
(Thermo Fisher Scientific, 1:50), Mouse Anti-H-2Kd PE Antibody (BD, 1:50). Single color 
controls were used for compensation. All analysis was performed with FlowJo, and gating strategy 
was shown in Supplemental Figure 5J. 
Flow cytometry of cell surface makers  
For cell surface marker analysis, 1-5 x 106 cells were dissociated with 0.02% EDTA in PBS, and 
washed and resuspended in PBS containing 1% BSA. Cells were then stained with primary 
antibodies (CD44, Bioxcell, 1:50; Integrin αV, Biolegend, 1:50; Integrin β1, DSHB, 1:50) for 20 
minutes on ice. After brief centrifugation and washes for two times with PBS containing 1% BSA, 
cells were incubated with Alexa Fluor-conjugated secondary antibodies (Thermo Fisher Scientific, 




Blue (Biolegend) and immediately analyzed. Samples were run on an LSR Fortessa X-20 (BD) 
and analyzed using FlowJo software (TreeStar). 
EFLUXX-ID® Green multidrug resistance assay 
The functions of the multidrug resistance proteins MDR1, MRP and BCRP were analyzed by 
eFluxx-ID Green Multidrug Resistance Assay Kit (ENZ-51029-K100, Enzo Lifesciences, 
Farmingdale, NY) according to the manufacturer’s instructions as previously reported (7). Briefly, 
after treatment, 2 x 105 cells were collected, washed with PBS and resuspended in complete growth 
medium without Phenol Red. Cells were then incubated with or without MDR inhibitors 
(verapamil for P-gp, MK-571 for MRP1, and novobiocin for BCRP, and DMSO for untreated 
control)  for 5 min at 37 °C, and incubated with the eFluxx-IDH Green dye for 30 min at 37 °C. 
Propidium iodide (PI) was added to the cells during the last 5 min of incubation for live cell 
detection. After data acquisition on LSR Fortessa X-20 (BD), the results were analyzed with 
FlowJo software. To quantify the transporter activity, the multidrug resistance factor (MAF) value 
was calculated using the following formula for each respective inhibitor: MAF = 100 x (MFI with 
inhibitor  - MFI control)/MFI with inhibitor, where MFI = mean fluorescence intensity. For each 
inhibitor, MAF values from three samples were used to calculate the mean MAF value. 
3D organoid culture 
Live EpCAM+ cancer cells were FACS (fluorescence-activated cell sorting) sorted from 
cryopreserved ovarian cancer patient specimen and subjected to 3D hydrogel encapsulation. For 
3D encapsulation, sorted EpCAM+ ovarian cancer cells were counted, pelleted for 5 minutes at 
600 x g, and homogeneously resuspended in ice-cold Cultrex (Trevigen) for a final cell 
concentration of 1000 cells/µL. For each hydrogel replicate, 20 µL of cell/Cultrex solution was 




diameter x 0.8 mm height) bonded to a circular 12 mm diameter glass cover slip, as previously 
reported (8). Hydrogel solutions were then incubated for 20 minutes at 37 °C to allow for Cultrex 
gelation. Following gelation, 700 µL of complete CAM CM or complete control medium was 
added to each well. Initial medium was supplemented with 2.5 µM GSK-3 inhibitor CHIR99021 
(Cayman Chemical) and 10 µM ROCK inhibitor Y27632 (STEMCELL Technologies) for the first 
three days in culture. Cell cultures were incubated at 37 °C and allowed to grow for 27 days. 
Culture medium was replaced every 3 days. 
           Paired primary CAM at 80% confluence was cultured for 72 hours, and the CAM CM was 
collected and filtered through 0.45 µm filter. This CAM CM was not concentrated. The filtered 
CAM CM was then mixed at 1:1 ratio with organoid formation medium to generate complete CAM 
CM. Complete control medium was generated from unconditioned medium containing 40% Ham's 
F-12, 40% Medium M199, 20% FBS, mixed with organoid formation medium at 1:1 ratio. 
           Organoid formation medium consisted of complete WENR medium (Advanced DMEM/F-
12 (Gibco) supplemented with 50% Wnt3a, R-spondin-1, and Noggin conditioned medium (L-
WRN cells; ATCC) with 1X GlutaMAX (Gibco), 1 mM HEPES (Thermo Fisher Scientific), 50 
ng/ml human EGF (Peprotech), 10 ng/ml human FGF2 (Peprotech), 10 ng/ml human FGF10 
(Peprotech), 10 mM Nicotinamide (Sigma), 1 mM N-Acetylcysteine (Sigma), 1X B27 Supplement, 
minus vitamin A (Gibco), 0.5 µM A83-01 (Sigma Aldrich), 1X Penicillin-Streptomycin-
Glutamine (Thermo Fisher Scientific), 10 nM Gastrin (Sigma Aldrich), 10 µM SB-202190 
(Peprotech), 100 µg/ml Normocin (Invivogen)).  
Immunostaining of 3D hydrogel organoids 
3D cultures in Cultrex hydrogels were fixed with 4% paraformaldehyde and 0.1% glutaraldehyde 




PBS for 1 minute and again for 15 minutes to quench any remaining glutaraldehyde, followed by 
two more washes in PBS. Samples were permeabilized with 0.1% Triton X-100 in PBS (PBST) 
for 1 hour and blocked with 10% goat serum in PBST for 4 hours, both at room temperature. 
Samples were incubated with primary antibody (ALDH1A1; Santa Cruz, 1:50) solution overnight 
at 4 °C. The following day, samples were washed three times and incubated at 4°C overnight with 
secondary antibody (anti-Mouse IgG Alexa Fluor 546; Invitrogen, 1:500). The following day, 
samples were washed three times with PBST. Next, 4′,6-diamidino-2-phenylindole (DAPI; Sigma 
Aldrich) and Alexa Fluor 647 phalloidin (F-actin stain; diluted in methanol; Invitrogen) were 
diluted in PBST for a final concentration of 2.5 µg/ml and 165 nM, respectively. Samples were 
incubated with DAPI and phalloidin for 1 hour at room temperature and subsequently washed three 
times. Samples were imaged using a Leica SPE confocal microscope.  
            The 3D volume image, covering a volume of 91x91x36.5 µm (voxel size: 0.089x0.089x0.5 
µm), was collected with a Nikon Eclipse Ti2-E inverted confocal microscope using a C2 mirror 
scanner, modified to include a coherent anti-Stokes Raman scattering (CARS) excitation/detection 
channel for lipid-specific imaging. The 3D rendering was created in NIS Elements. 
Immunostaining of paraffin embedded organoids 
3D cultures in Cultrex hydrogels were fixed with 4% paraformaldehyde and 0.1% glutaraldehyde 
in PBS for 24 hours at 4°C. Following fixation, samples were washed with 200 mM glycine in 
PBS for 1 minute and again for 15 minutes to quench any remaining glutaraldehyde, followed by 
two more washes in PBS for 15 minutes each. Hydrogels were removed from the silicone molds, 
transferred to a histology cassette, and submerged in 70% ethanol. Samples were provided to the 
Stanford Human Pathology/Histology Service Center for paraffin embedding, sectioning, and 




of unstained sections, slides were placed in xylene, gradient ethanol, and then DI water. For antigen 
retrieval, slides were submerged in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween-
20, pH 6.0) and incubated in a steamer (IHC World) for 45 minutes. After allowing slides to cool, 
samples were washed three times with PBS, permeabilized with 0.2% Triton X-100 in PBS for 15 
minutes, and blocked with 10% goat serum in 0.2% Triton X-100 in PBS for 2 hours, all at room 
temperature. Primary antibodies (CD44, Bioxcell, 1:50; Pan-cytokeratin, Abcam, 1:100; 
Cytokeratin 8, DSHB, 1:25; EpCAM, Abcam, 1:50) diluted at 1:100 were incubated with samples 
overnight at 4°C. Samples were then washed with PBST five times for 5 minutes each at room 
temperature. Secondary antibodies (anti-Rabbit IgG Alexa Fluor 488, anti-Rat IgG Alexa Fluor 
647, anti-Rat IgG Alexa Fluor 546, anti-Rabbit IgG Alexa Fluor 647, Thermo Fisher Scientific, 
1:500) and DAPI (Sigma Aldrich, 2.5 µg/ml) were diluted in PBST and incubated with samples 
for 2 hours at room temperature. Samples were again washed with PBST five times and mounted 
using ProLong Gold Antifade Reagent (Cell Signaling Technologies). Samples were imaged using 
a Leica SPE confocal microscope. 
Immunostaining of OPN in cell cultures 
Cells were cultured into 8-well chamber slide (Thermo Fisher Scientific), and fixed in 4% 
paraformaldehyde for 20 minutes. Cells were permeabilized with 0.2% Tween-20 in PBS, blocked 
in serum-free protein block (Dako) for 10 minutes at room temperature, and then stained in primary 
antibody (Rabbit Anti-osteopontin Antibody, Abcam, 1:100) solution at room temperature for 1 
hour. After washing, secondary antibodies conjugated with Alexa Fluor Dyes (Anti-rabbit Alexa 
Fluor 555 Secondary Antibody, 1:400) were added for 30 minutes at room temperature. DAPI 
(Sigma Aldrich) was used for nuclear counterstaining at 0.1 µg/ml. Fluorescence images were 




scanner. DAPI (nuclei) were excited at 405 nm and detected in the range 440-475 nm. Alexa Fluor 
555 (OPN) was excited at 561 nm and detected in the range 575-610 nm. Stitched 3D images (4x4 
stacks) covering a total volume of 408x408x20 µm (3789x3789x5 pixels) were randomly collected 
with a voxel size of (0.11x0.11x4 µm). Images were pre-processed and analyzed using ImageJ. 
Briefly, following Gaussian blurring and max projection, the cell nuclei were identified by Li 
thresholding. Connecting nuclei were separated by the Ellipse Split plug-in, using a standard 
watershed routine. Nuclei were used as seeds for Voronoi segmentation of the cells. The mean 
fluorescence intensity was calculated for each cell. Forty-three LP9 cells and 186 OC8 cells were 
evaluated.  
Immunostaining of human specimens  
Formalin-fixed, paraffin-embedded samples were sectioned to 4-5 µm thickness, and the slides 
were deparaffinized in xylene and rehydrated through graded ethanol solutions. Antigen retrieval 
was conducted in pressure cooker for 10 minutes using sodium citrate buffer (10 mM sodium 
citrate, 0.05% Tween-20, pH 6.0).  Slides were then blocked with serum-free protein block (Dako) 
for 10 minutes at room temperature to reduce non-specific staining. After blocking, samples were 
performed staining at 4°C overnight using primary antibodies (Rabbit Anti-osteopontin Antibody, 
Abcam, 1:100; Mouse anti-calretinin Antibody, Invitrogen, 1:50) diluted in PBS with 1% BSA 
and 0.05% Tween-20. On the next day, slides were incubated with Alexa Fluor-conjugated anti-
mouse and anti-rabbit secondary antibodies (Thermo Fisher Scientific, 1:500) diluted in PBS with 
1% BSA and 0.05% Tween-20 for 1 hour at room temperature. 0.2% Sudan Black B solution in 
70% ethanol was then added to the slides through syringe filter for 10 minutes to quench 
background fluorescence. DAPI (Sigma Aldrich) was used for nuclear counterstaining at 0.1 µg/ml 




For total ascites cells, single cell suspension was suspended in 100µL PBS and were deposited by 
cytospin onto glass slides. Cells were then fixed in 10% formalin for 20 mins, and blocked (30 
min with normal serum). Cells were permeabilized with 0.2% Tween-20 in PBS, blocked in serum-
free protein block (Dako) for 10 minutes at room temperature, and then stained in primary antibody 
(Rabbit Anti-osteopontin Antibody, Abcam, 1:100; Mouse Anti-calretinin Antibody, Invitrogen, 
1:50) solution at room temperature for 1 hour. After washing, anti-rabbit and anti-mouse secondary 
antibodies conjugated with Alexa Fluor Dyes were added for 30 minutes at room temperature. 
DAPI (Sigma Aldrich) was used for nuclear counterstaining at 0.1 µg/ml and images were taken 
under Leica SPE microscope. 
Immunostaining of mouse xenografts  
Staining was performed on formalin-fixed, paraffin-embedded xenograft sections using the 
protocol described above for human omental specimens. Generally, sections were incubated with 
primary antibody against cleaved caspase-3 (Cell Signaling Technologies, 1:100), γ-H2AX (Cell 
Signaling Technologies, 1：500)  or  cisplatin-DNA adduct (Abcam, 1:100) at 4°C overnight, and 
incubated with Alexa Fluor-conjugated Anti-rabbit or Anti-rat Antibody (Thermo Fisher Scientific, 
1:500) for 1 hour at room temperature. DAPI (Sigma Aldrich) was used for nuclear counterstaining. 
at 0.1 µg/ml on the slides and images were taken under the Leica SPE microscope.  
Bioinformatics 
GSE84829 was obtained from the Gene Expression Omnibus (GEO) and analyzed for DEGs in 
HPMCs and CAMs. GSE30587 was obtained from the GEO database and analyzed for OPN 
correlation with Calretinin on human omental metastatic tissues. For GSE9891 from the GEO 




analyzed for peritoneal site gene expression correlations. Correlation analysis of gene expression 
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Supplemental Figure 1. Cancer associated mesothelial cells promote ovarian cancer cell cisplatin 
resistance. 
(A) Immunofluorescence of cell type markers in primary mesothelial cells isolated from ovarian cancer 
patients. Nuclei were stained with DAPI (blue). Scale bars, 100 µm. (B) Morphology of primary isolated 
mesothelial cells in culture in the presence or absence of EGF. Scale bars, 400 µm. (C-E) Effect of LP9 co-
injection on cisplatin resistance of OVCAR8 in vivo. OVCAR8 or OVCAR8 plus LP9 cells were injected 
subcutaneously into female immunodeficient mice and treated with or without cisplatin every 3 days for 
three cycles. Tumor growth curve is shown in C (n = 7-11 mice per group, mean ± SEM; **p<0.01, ns, not 
significant; two-tailed Student’s t-test). Representative xenograft images are shown in D. Xenograft weights 









Supplemental Figure 2. Cancer associated mesothelial secreted factor(s) promote ovarian cancer 
cisplatin resistance. 
(A) Schematic of the experimental approach showing the interaction between mesothelial cells and cancer 
cells in the indirect co-culture system. The 0.4 µm pore size insert allows mutual media exchange and 
avoids physical contact of two cell types. After co-incubation, chemotherapeutic drugs such as cisplatin 
was added only to the cancer cells, and the cancer cells were checked for phenotypic changes. (B-C) Effect 
of LP9 or LP3 co-culture on cisplatin sensitivity of OVCAR8. Cell viability is normalized to its untreated 
control (n=4-5; mean ± SEM; ***p<0.001 versus OVCAR8 monoculture; two-way ANOVA test).  (D) 
CAM2 cells were co-cultured with OVCAR8 at ratios (1:1, 3;1, 5:1), and OVCAR8 cells were measured 
for cisplatin sensitivity after co-culture (n=3; mean ± SEM; ***p<0.001 versus OVCAR8 monoculture; 
two-way ANOVA test). (E-F) The percentage of Annexin V+ apoptotic OVCAR8 cells with or without 
LP9 preconditioning. Representative image of Annexin V assay is shown in E, and quantification is shown 






Supplemental Figure 3. Cancer associated mesothelial cells secreted factor(s) to promote ovarian 
cancer multidrug chemoresistance. 
(A-B) Cell viability of OC8 and OVCAR8 cells treated with carboplatin after LP9 or LP3 co-culture (n=3). 
(C-D) Cell viability of OC8 and OVCAR8 treated with paclitaxel after LP9 or LP3 co-culture (n=3; mean 







Supplemental Figure 4. Secreted factor(s) from cancer associated mesothelial cells, but not HPMCs, 
promote ovarian cancer chemoresistance. 
 (A-C) Effect of conditioned media (CM) from HPMCs or cancer associated mesothelial cells on the 
cisplatin sensitivity of OVCAR8, CAOV3 or SNU119 cells. Cell viability is normalized to its untreated 








Supplemental Figure 5. Cancer associated mesothelial cells promote ovarian cancer stemness. 
(A) Effect of CAM1 co-injection on tumor incidence of OC8 injected subcutaneously in immunodeficient 
mice. (B) Effect of LP9 co-injection on tumor incidence of OVCAR8 injected subcutaneously in 
immunodeficient mice. (C) Sphere formation assay of OC8 after LP3 co-culture. Representative sphere 
images are shown on the left. Quantification of sphere number are shown as fold increase on the right (n=10; 
mean ± SEM; ***p<0.001; two-tailed Student’s t-test). Scale bar, 200 µm. (D-E) Sphere formation assay 
of OVCAR8 after LP9 or LP3 co-culture. Representative sphere images are shown on the left. 
Quantification of sphere number are shown as fold increase on the right (n=10; mean ± SEM; **p<0.01, 
***p<0.001; two-tailed Student’s t-test). Scale bar, 200 µm. (F-H) Relative mRNA quantification of 
stemness markers NANOG, OCT3/4, SOX2 and ALDH1A in OVCAR8 with or without LP9 co-culture (F); 
OC8 and OVCAR8 cells with or without LP3 co-culture (G); OVCAR8 with or without CAM2 co-culture 
(H) as normalized to GAPDH mRNA in real-time PCR analysis (n=3; mean ± SEM; **p<0.01, ***p<0.001; 
two-tailed Student’s t-test).  (I) Aldefluor assay showing the proportion of ALDH+ cells in OC8 and 
OVCAR8 with or without LP9 co-culture in vitro. (n=3; mean ± SEM; *p<0.05, **p<0.01; two-tailed 
Student’s t-test). (J-K) Flow cytometry gating strategy of Aldefluor assay in live EpCAM+ tumor cells in 
vivo (J). Cells were gated by SSC-A vs FSC-A to rule out debris and FSC-H vs FSC-A for singlets. The 
singlets were then gated by PE-H-2Kd for human cells and APC-EpCAM for epithelial cells. The DEAB 
added sample serves as a control for each tested sample in Aldefluor assay. K shows the frequency of 
ALDH+ cells in EpCAM+ population of OVCAR8 xenografts with or without LP9 co-injection in vivo 
measured by Aldefluor assay (n=6 mice per group, mean ± SEM; **p<0.01; two-tailed Student’s t-test). 
(L) Aldefluor assay showing the frequency of ALDH+ cells in EpCAM+ population of OC8 xenografts with 
or without pretreatment of LP9 co-culture (n=5 mice per group, mean ± SEM; **p<0.01; two-tailed 
Student’s t-test). (M) Immunofluorescent staining of pan-cytokeratin (magenta) and CD44 (green) in 










Supplemental Figure 6. Cancer associated mesothelial cells secrete osteopontin. 
(A) Effect of fractionated and proteinase K digested LP9 conditioned media (CM) on OC8 cell viability 
upon cisplatin treatment (n=3; mean ± SEM; *p<0.05, ***p<0.001 versus control media, ns, not significant; 
two-way ANOVA test). (B) Cytokine array in LP9 CM and OVCAR8 CM. Circles highlight cytokine of 
the highest fold change in each individual color. (C) Real time PCR analysis of relative mRNA expression 
of OPN in LP9 and LP3 CAMs, and ovarian cancer cells as normalized to GAPDH mRNA (n=3; mean ± 
SEM). (D) Quantification of OPN concentration in LP3 and ovarian cancer cell CM by ELISA. (n=3; mean 
± SEM). (E-F) Representative images of OPN (gold) immunofluorescence in LP9 and OC8 are shown in 
E. DAPI was stained in magenta. Single cell quantification of mean OPN fluorescence intensity per cell is 
shown in F (n=43 in LP9, n=184 in OC8; mean ± SEM; ***p<0.001; two-tailed Student’s t-test). Scale 
bars: 50 µm. (G) Representative immunofluorescent images of OPN (red) in CAM1, CAM2, LP9 and OC8. 
Scale bars, 100 µm. DAPI was stained in blue. (H-I) Immunofluorescence of OPN (green) and mesothelial 
cell marker calretinin (red) on control omentum from non-cancerous donors, or omentum with ovarian 
cancer (OvCa) metastasis from HGSOC patient. Arrows denote mesothelial cells or CAMs, asterisks mark 
metastasizing cancer cells in proximity. Nuclei were stained with DAPI (blue). Scale bars: 100 µm. (J) 
Correlation of OPN expression with Calretinin expression in human serous-type ovarian cancer peritoneal 
metastases (GSE9891, n=42; Pearson correlation). (K) Correlation of OPN expression with Calretinin 
expression in human serous ovarian cancer omental metastasis samples (GSE30587, n=9; Pearson 
correlation). (L) Kaplan-Meier curves of overall survival in ovarian cancer patients according to the median 














Supplemental Figure 7.  Osteopontin promotes ovarian cancer chemoresistance and stemness.  
(A) Effect of exogenous OPN on cisplatin sensitivity of OVCAR8. Cell viability is normalized to its 
untreated control (n=3-5; mean ± SEM; ***p<0.001 versus untreated control; two-way ANOVA test). (B-
C) Sphere formation assay of OVCAR8 after OPN exposure. Representative sphere images and 
quantification of sphere number fold increase are shown (n=10; mean ± SEM; ***p<0.001; two-tailed 
Student’s t-test). Scale bar, 200 µm.  (D) Real time PCR analysis showing relative mRNA expression of 
stemness markers NANOG, OCT3/4, SOX2 and ALDH1A1 in OVCAR8 after OPN exposure, as normalized 











Supplemental Figure 8. Genetic inhibition of osteopontin reduces cancer associated mesothelial cell 
mediated ovarian cancer cisplatin resistance. 
(A) Relative mRNA quantification of OPN expression in LP9 shControl and LP9 shOPN normalized to 
GAPDH mRNA as determined by real-time PCR (n=3; mean ± SEM; ***p<0.001 versus LP9 shControl; 
one-way ANOVA). (B) Cell viability of LP9 shOPN as normalized to shControl LP9 cell viability. (n=4; 
mean ± SEM; ns, not significant, versus LP9 shControl; one-way ANOVA test). (C) OC8 cells were 
exposed to LP9 shControl conditioned media (CM), LP9 shOPN CM or LP9 shOPN CM added with 
exogenous OPN, and tested for cell sensitivity to cisplatin. Cell viability of each group is normalized to its 
untreated control (n=3; mean ± SEM; **p<0.01, ***p<0.001 versus LP9 shControl CM, ns, not significant; 
two-way ANOVA test). (D) Cell viability of OVCAR8 cells treated with cisplatin after co-culture with LP9 
shControl or LP9 shOPN. Cell viability is normalized to its untreated control (n=6; mean ± SEM; 










Supplemental Figure 9. Genetic inhibition of osteopontin reduces cancer associated mesothelial cell 
mediated ovarian cancer stemness. 
(A-B) Sphere formation assay of OVCAR8 after co-culture with LP9 shControl or LP9 shOPN. 
Representative sphere images and quantification of sphere number fold increase are shown (n=6; mean ± 
SEM; *p<0.05 versus LP9 shControl; one-way ANOVA test). Scale bar, 200 µm.  (C) Sphere formation 
assay of OC8 after co-culture with LP9 shControl or LP9 shOPN. Representative sphere images of sphere 
number fold increase are shown. Scale bar, 200 µm. (D) Real time PCR analysis showing relative mRNA 
expression of stemness markers NANOG, OCT3/4, SOX2 and ALDH1A1 in OVCAR8 with LP9 shControl 
or LP9 shOPN co-culture, as normalized to GAPDH mRNA (n=3; mean ± SEM; ***p<0.001 versus LP9 






Supplemental Figure 10. CD44 and integrin expression on ovarian cancer cells co-cultured with 
cancer associated mesothelial cells. 
(A) Percentage of CD44+ cell OC8 and OVCAR8 cells with or without LP9 co-culture determined by flow 
cytometry. (B) Percentage of integrin αV+ OC8 and OVCAR8 cells with or without LP9 co-culture 
determined by flow cytometry. (C) Percentage of integrin β1+ OC8 and OVCAR8 cells with or without LP9 
co-culture determined by flow cytometry. (D-E) Quantification of CD44+ percentages and CD44 median 
fluorescence intensity (MFI) in OC8 and OVCAR8 cells with or without LP9 co-culture (n=3; mean ± SEM; 
*p<0.05, ***p<0.001; two-tailed Student’s t-test). (F) Relative mRNA quantification of CD44 in OC8 and 
OVCAR8 cells with or without LP9 co-culture as normalized to GAPDH mRNA by real-time PCR. (n=3; 
mean ± SEM; **p<0.01, ***p<0.001; two-tailed Student’s t-test). (G-H) Percentage of integrin αV+ and 
integrin β1+ OC8 and OVCAR8 cells with or without LP9 co-culture. (n=3; mean ± SEM; ***p<0.001, ns, 












Supplemental Figure 11. CD44 receptor blockade reduces cancer associated mesothelial-induced 
ovarian cancer chemoresistance. (A-C) Effect of an anti-CD44 blocking antibody, integrin-blocking 
RGD peptide, or their combination on LP9 CM-mediated cisplatin resistance of CAOV3, SNU119 or 
OVCAR8 cells. RGE was used as control for RGD (n=4; mean ± SEM; **p<0.01, ***p<0.001 versus LP9 







Supplemental Figure 12. CD44 receptor blockade reduces osteopontin-induced ovarian cancer 
chemoresistance. (A-D) Effect of an anti-CD44 blocking antibody, integrin-blocking RGD peptide, or 
their combination on OPN-mediated cisplatin resistance of OC8, CAOV3, SNU119 or OVCAR8 cells. 
RGE was used as control for RGD (n=4; mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 versus OPN + 







Supplemental Figure 13. CD44 receptor blockade reduces cancer associated mesothelial-induced 
ovarian cancer stemness. (A) Effect of an anti-CD44 blocking antibody, integrin-blocking RGD peptide, 
or their combination on LP9 CM-mediated sphere formation increase of OC8 cells. Representative images 
are shown. Scale bar, 200 µm. (B-C) Effect of an anti-CD44 blocking antibody, integrin-blocking RGD 
peptide, or their combination on LP9 CM-mediated sphere formation increase of OVCAR8 cells. 
Representative images are shown in B. Scale bar, 200 µm. Quantification of fold increase is shown in C 




















Supplemental Figure 14. Cancer associated mesothelial cells promotes ovarian cancer 
chemoresistance through osteopontin, PI3K-AKT signaling and ABC transporter activity. 
(A) Western blot analysis of PI3K-AKT pathway in OVCAR8 cells co-cultured with LP9 shControl or LP9 
shOPN cells. (B) Western blot analysis of PI3K-AKT pathway in SNU119 cells treated with exogenous 




exogenous OPN-mediated cisplatin resistance of OVCAR8, CAOV3 or SNU119 cells (n=4; mean ± SEM; 
**p<0.01, ***p<0.001 versus exogenous OPN; two-way ANOVA test). (F) Fold increase of relative 
mRNA expression of ABC transporters in OVCAR8 with LP9 co-culture versus OVCAR8 monoculture, 
as normalized to GAPDH mRNA in real-time PCR analysis (n=3; mean ± SEM; *p<0.05, **p<0.01, ns, 
not significant; two-tailed Student’s t-test). (G-I) EFLUXX-ID® Green multidrug resistance assay by flow 
cytometry detecting the activities of three major types of ABC transporters (MDR1, MRP and BCRP) in 
OVCAR8 cells treated with LP9 conditioned media (CM) and/or anti-OPN blocking antibody (G); in 
SNU119 cells treated with LP9 CM and/or anti-CD44 blocking antibody (H); and in OVCAR8 cells treated 
with LP9 CM and/or PI3K-AKT pathway inhibitor LY294002 (I). Multidrug resistance activity factor 
(MAF) indicative of corresponding ABC protein activity is shown (n=3; mean ± SEM; *p<0.05, 

















































Supplemental Figure 15. An anti-OPN neutralizing antibody reduces cancer associated mesothelial 
cell mediated ovarian cancer chemoresistance. 
(A) Effect of an anti-OPN neutralizing antibody or control antibody on LP9 or LP3 conditioned media 
(CM)-mediated OC8 resistance to cisplatin (n=3; mean ± SEM; **p<0.01, ***p<0.001 versus LP9 or LP3 
CM + control Ab; ns, not significant; two-way ANOVA test). (B) Effect of an anti-OPN neutralizing 
antibody or control antibody on CAM1 CM-mediated OC8 resistance to cisplatin (n=3; mean ± SEM; 
**p<0.01, ***p<0.001 versus CAM1 CM + control Ab; two-way ANOVA test). (C) Effect of 
preincubation with an anti-OPN antibody in the absence or presence of LP9 conditioned media 
(CM) on OC8 subcutaneous tumor incidence in immunodeficient mice (n=18 mice per group).  (D) 
Immunofluorescence of OPN (green) and mesothelial cell marker calretinin (red) in total ascites cells from 

















Supplemental Table 1. Patient characteristics of primary isolated CAMs 
 
CAM ID Age Pathology Chemotherapy treatment Source 
CAM1 39 Recurrent Low Grade Serous Cancer Multiple Ascites 

























Supplemental Table 2. Clinicopathological information and treatment history of the ovarian cancer 







# Pathology Age Stage Chemotherapy 
treatment 
Calretinin+ (%) 
in total ascites cells 
1 High grade serous adenocarcinoma 59 IIB Chemonaive 80.81 
2 High grade serous adenocarcinoma 67 IIIC Chemonaive 41.42 
3 High grade serous ovarian cancer 72 IIIC Neoadjuvant 16.02 
4 Recurrent high grade serous carcinoma 49 IIIC Multiple 31.91 
5 High grade serous carcinoma 66 IVA Chemotherapy 34.56 
6 High grade serous carcinoma 36 IVB Chemonaive 15.68 
7 High grade serous carcinoma 52 IVB Neoadjuvant 13.97 
8 High grade serous carcinoma 38 IIIB Neoadjuvant 37.79 
9 High grade serous carcinoma 71 IIIA Neoadjuvant 8.56 
10 High grade serous carcinoma 71 IIIC Chemonaive 10.92 
11 High grade serous carcinoma 63 IIIC Chemonaive 21.51 
12 High grade serous carcinoma 52 IIIC Chemonaive 23.01 
13 High grade serous carcinoma 70 IIIC Neoadjuvant 8.61 







Supplemental Table 3. Chemicals, drugs and reagents in this study 
 
Chemicals, Drugs and Reagents Source Identifier 
Proteinase K Thermo Fisher Scientific Cat# 25530049 
RGD Abcam Cat# ab142698 
RGE(S) Sigma Aldrich Cat# A5686 
Alexa Fluor 647 phalloidin Thermo Fisher Scientific Cat# A22287 
DAPI Sigma Aldrich Cat# D9542 
Matrigel Corning Cat# 356237 
Cultrex Trevigen Cat# 3533-001-02 
GlutaMAX Gibco Cat# 35050061 
Poly-L-lysine Sigma Aldrich Cat# P4707 
B27 Invitrogen Cat# 425305 
Insulin Sigma Aldrich Cat# 91077C 
EGF Thermo Fisher Scientific Cat# PHG0313 
EGF Peprotech Cat# AF-100-15 
Penicillin-Streptomycin-Glutamine Thermo Fisher Scientific Cat# 10378016 
HEPES Thermo Fisher Scientific Cat# 15630080 
CHIR99021 Cayman Chemical Cat# 13122 
B27 minus vitamin A Gibco Cat# Gibco 12587010 
SB-202190 Peprotech Cat# 1523072 
N-Acetylcysteine Sigma Aldrich Cat# A9165 
Nicotinamide Sigma Aldrich Cat# N0636 
Normocin Invivogen Cat# ant-nr-1 
FGF-basic Sigma Aldrich Cat# F0291 
A83-01 Sigma Aldrich Cat# SML0788 
FGF-10 Peprotech Cat# 100-26 
FGF-basic Peprotech Cat# 100-18B 
Y27632 STEMCELL Technologies Cat# 72302 
SytoxTM Blue Biolegend Cat# 425305 
Cisplatin WG Critical Care Cat# 44567-511-01 
Carboplatin Teva Parenteral Medicines Cat# 0703-4244-01 
Paclitaxel Teva Parenteral Medicines Cat# 0703-4766-01 
LY294002 Cell Signaling Technologies Cat#9901S 
TGFβ1 Peprotech Cat#100-21 

















Supplemental Table 4. Antibodies used in this study 
 
Antibody Source Identifier 
Rabbit Anti-EpCAM Antibody 
[EPR677(2)] 
Abcam Cat# ab124825; RRID:AB_10973714 
Mouse Anti-FSP1 Antibody Clone 1481 Novus Biologicals Cat# NBP2-53178 




Cat# MA3-745, RRID:AB_326285 
Rabbit Anti-CD31 Antibody Abcam Cat# ab28364, RRID:AB_726362 
Mouse Anti-CD45 Antibody (2D1) Thermo Fisher 
Scientific 
Cat# 11-9459-42, RRID:AB_1907394 
Rabbit Anti-cytokeratin 8 Antibody 
[EP1628Y] 
Abcam Cat# ab53280; RRID:AB_869901 
Mouse Anti-calretinin Antibody (Z11-E3) Invitrogen Cat# 180291 
Rabbit Anti-osteopontin Antibody Abcam Cat# 8848, RRID:AB_306566 
Rabbit Anti-cleaved caspase 3 Antibody Cell Signaling 
Technologies 
Cat# 9661, RRID:AB_2341188 
Rabbit Anti-caspase 3 Antibody Cell Signaling 
Technologies 
Cat# 9662, RRID:AB_331439 
Rabbit Anti-GAPDH Antibody (D16H11) Cell Signaling 
Technologies 
Cat# 5174, RRID:AB_10622025 
Rabbit Anti-ERK1/2 Antibody (137F5) Cell Signaling 
Technologies 
Cat# 4695, RRID:AB_390779 




Cat# 4376, RRID:AB_331772 




Cat# 9145, RRID:AB_2491009 
Rabbit Anti-STAT3 Antibody (79D7) Cell Signaling 
Technologies 
Cat# 4904, RRID:AB_331269 
Rabbit Anti-PARP Antibody Cell Signaling 
Technologies 
Cat# 9542, RRID:AB_2160739 
Rabbit Anti-Akt Antibody Cell Signaling 
Technologies 
Cat# 9272, RRID:AB_329827 
Rabbit Anti-phospho-Akt Antibody Cell Signaling 
Technologies 
Cat# 9271, RRID:AB_329825 
Mouse Anti-PI3K Antibody Clone 4 BD Cat# 610045, RRID:AB_397459 
Rabbit Anti-phospho-PI3K Antibody Cell Signaling 
Technologies 
Cat# 4228, RRID:AB_659940 
Anti-mouse IgG, HRP-linked Antibody Cell Signaling 
Technologies 
Cat# 7076, RRID:AB_330924 
Anti-rabbit IgG, HRP-linked Antibody Cell Signaling 
Technologies 
Cat# 7074, RRID:AB_2099233 
Mouse Anti-ALDH1A1 Antibody (H-4) Santa Cruz Cat# sc-374076, RRID:AB_10916407 
Rat Anti-CD44 Antibody (Hermes-1) Bioxcell Cat# BE0262, RRID:AB_2687741 
Rat IgG2a Isotope Control Antibody Bioxcell Cat# BE0089, RRID:AB_1107769 
Rabbit Wide Spectrum Anti-cytokeratin 
Antibody 
Abcam Cat# ab9377, RRID:AB_307222 








Cat# 9718, RRID:AB_2118009 




Cat# A-11008, RRID:AB_143165 




Cat# A-21247, RRID:AB_141778 




Cat# A-11081, RRID:AB_2534125 




Cat# A-21245, RRID:AB_2535813 




Cat# A-11007, RRID:AB_10561522 




Cat# A-11012, RRID:AB_2534079 




Cat# A-21208, RRID:AB_2535794 




Cat# A-31571, RRID:AB_162542 




Cat# A-21202, RRID:AB_141607 




Cat# A-21428, RRID:AB_2535849 
Goat Anti-osteopontin Antibody R&D Cat# AF1433, RRID:AB_354791 
Goat IgG Control Antibody R&D Cat# AB-108-C, RRID:AB_354267 
Mouse Anti-H-2Kd PE Antibody Clone 
SF1-1.1 
BD Cat# BDB562004 




Cat# 50-9326-42, RRID:AB_10598658 
 
Rat Anti-cisplatin-DNA Antibody Clone 
CP9/19 
Abcam Cat# 103261, RRID:AB_10715243 
 
Rabbit Anti-calretinin Antibody (SP13) Thermo Fisher 
Scientific 
Cat# MA5-14540, RRID:AB_10985167 




























Supplemental Table 5. Primers for real-time PCR analysis 
 
Gene Symbol Forward Primer (5’- 3’) Reverse Primer (5’- 3’) 
ALDH1A1 CACGCCAGACTTACCTGTCC TCCTCCTCAGTTGCAGGATT 
OCT3/4 TTCAGCCAAACGACCATCTG GAACCACACTCGGACCACATC 
SOX2 CACACTGCCCCTCTCACACAT CCCATTTCCCTCGTTTTTCTT 
NANOG CACCAGTCCCAAAGGCAAAC GCCTTCTGCGTCACACCATT 
OPN AGAAGTTTCGCAGACCTGACA AACGGGGATGGCCTTGTATG 
CD44 CCAATGCCTTTGATGGACCA TGTGAGTGTCCATCTGATTC 
MDR1 GCCTGGCAGCTGGAAGACAAATAC CCATACCAGAAGGCCAGAGCATAA 
MDR4 TGGCCCTGGTTGGAAGTAGTG AGAAGGATCTTGGGGTTGCGAA 
MRP6 CACTGCGCTCCAGGATCAGC CAGACCAGGCCTGACTCCTG 
MRP5 AGAGGTGACCTTTGAGAACGCA CTCCAGATAACTCCACCAGACGG 
MRP4 TTCAGTGTGCTGGGATGAGGT TCAGTGATGAGAACAACTTCC 
MRP3 GCTCAAGATGGTCCTGGGTGT CAGGGCAAAGTGGATGTAGAA 
MRP2 GGGAAGTTGATGAAGAGATGA GGAATGATTTCAGGAGCACCA 
MRP1 AGTGGAACCCCTCTCTGTTTAAG CCTGATACGTCTTGGTCTTCATC 




































Supplemental Video 1. 3D rendering of ovarian cancer organoids formed with CAM CM. 
A volume rendering of a confocal fluorescence/coherent anti-Stokes Raman scattering (CARS) 3D 
microscopy image covering a volume of 91x91x36.5 µm (voxel size: 0.089x0.089x0.5 µm), visualizing the 
cellular build-up and external/luminal composition of a 27-day human ovarian cancer organoid with a 
diameter of 73 µm. At this stage, the cells represented by their nuclei (DAPI, blue) display a highly 
polarized organization of their components. While their F-actin network (Alexa Fluor 647, magenta) and 
intracellular lipid stores (CARS, yellow) face the luminal side of the organoid, the stem cell marker 
ALDH1A1 (Alexa Fluor 546, red) is organized between the cells and on the external side. The organoid 
was optically - not physically – sectioned. 
 
